Revance Therapeutics Inc (RVNC)

[Lishur]

I hope I made the bull case for both the patient and provider in switching to Daxxify. I don't believe a lot of the analysts have truly worked the numbers to see the cost/benefit analysis in a clear way. This will become abundantly clear as new injectors gain confidence in their injection patterns and amounts as they follow up with their patients over the first 6 months, manage client expectations, and price it per unit as Revance recommends.

Very very wrong timing...you made this post right when RVNC was about to fall off the cliff.. Well Done